Role NLRP3 Inflammasome in Weight Loss Following Sleeve Gastrectomy in Morbidly Obese Patients
Launched by UNIVERSITY HOSPITAL CENTER OF MARTINIQUE · Mar 22, 2021
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how inflammation in the body affects weight loss after a specific type of weight loss surgery called sleeve gastrectomy, particularly in women who are severely obese. The researchers believe that the amount of inflammation in fat tissue before surgery may influence how much weight a person loses and how well they maintain that weight loss afterward. This study is important because while sleeve gastrectomy can help many people lose weight and improve health, some patients do not experience the expected benefits.
To participate in this trial, women between the ages of 18 and 45 who have a body mass index (BMI) of 40 or more (or 35 with certain health issues) may be eligible. Participants will receive thorough information about the surgery and its risks, and they will be followed closely for two years after the operation. This study aims to understand better how inflammation affects weight loss, which could lead to improved treatments for obesity and related health problems in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Being a woman between the ages of 18 and 45;
- • Have been well informed about bariatric surgery and perioperative risks and have benefited from a multidisciplinary evaluation by a multidisciplinary team (RCP) ;
- • Have a BMI greater than or equal to 40 kg/m2 or greater than or equal to 35 kg/m2 with at least one co-morbidity that can be improved after surgery (cardiovascular disease, sleep apnea and severe respiratory disorders, type 2 diabetes, osteoarticular diseases)
- • Have been informed of the research on the samples taken during care;
- • Having stated its decision not to object to the research on the samples taken during the treatment;
- • To have accepted medical and surgical follow-up for 24 months;
- • Patient under the general social security system.
- Exclusion Criteria:
- • Being a pregnant or nursing woman;
- • Being a type 1 diabetic;
- • Have inflammatory bowel disease;
- • Have severe and unstable eating disorders ;
- • Have severe, uncontrolled cognitive, mental or psychological disorders;
- • Have a cancerous pathology;
- • Be addicted to alcohol and psychoactive substances (both legal and illegal);
- • Have a life-threatening illness in the short or medium term;
- • Have contraindications related to surgical operations in general such as general anaesthesia;
- • Be under legal protection measures (guardianship, curators, safeguarding of justice), and person deprived of liberty.
About University Hospital Center Of Martinique
The University Hospital Center of Martinique (CHUM) is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent academic hospital, CHUM integrates cutting-edge research with clinical practice, fostering collaborations among healthcare professionals, researchers, and academic partners. The center is committed to enhancing health outcomes in the Caribbean region by focusing on a diverse range of medical disciplines, ensuring the highest standards of ethical conduct and patient safety in all trials. Through its comprehensive approach, CHUM aims to contribute significantly to medical knowledge and the development of effective treatment options for various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fort De France, , Martinique
Patients applied
Trial Officials
Rémi NEVIERE, MD, PhD
Study Chair
CHU de Martinique
Emmanuel RIVKINE
Principal Investigator
CHU de Martinique
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials